Cleveland HeartLab announces speakers for its fourth annual symposium on cardiovascular disease, preventive medicine

CLEVELAND, Aug. 28, 2013 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its fourth annual symposium, Where Inflammation Meets Lipids®, will focus on unique models and strategies for assessing, treating and preventing chronic disease.

The symposium, one of the premier meetings of its kind, will be held at the Irving Convention Center in Dallas on Oct. 17-18, 2013.  Cleveland HeartLab’s annual educational symposium attracts hundreds of the best primary care practitioners in the United States who are focused on wellness and prevention.  This year’s program also is attracting leaders from industry with similar goals, including improving patient outcomes and reducing costs.

The company said 17 thought-leading experts will speak at this year’s program, engaging symposium participants on a range of topics related to cardiovascular disease.  This year’s meeting also includes a special reception at Cowboys Stadium, complete with interactive agility events.

In addition to panel discussions, attendees will be able to participate in unique expert-led case study sessions designed to maximize attendee participation.   The symposium has been approved for 12 continuing medical education credits by the American Academy of Family Physicians.

The symposium’s featured speakers and the title of his or her talk include:

• Kavita Patel, M.D., director of policy, White House Office of Intergovernmental Affairs and Public Engagement, Thriving in Health Care Reform
• Michael Roizen, M.D., New York Times best-selling author of The Real Age, and chairman, Cleveland Clinic Wellness Institute, Wellness Works: Models and Strategies that Work
• Connie Mariano, M.D., former director, White House Medical Unit and physician to the president, Taking Care of the First Patient
• Emad Rizk, M.D., president, McKesson Health Solutions, Navigating the Complexity of New Value-Based Reimbursement Models

Other thought-leaders confirmed as speakers include Miles Snowden, M.D., chief medical officer, Optum; Mimi Guarneri, M.D., founder, Scripps Center for Integrative Medicine; The Hon. Tommy Thompson, former secretary, U.S. Department of Health and Human Services; and Marc Penn, M.D., Ph.D., chief medical officer, Cleveland HeartLab Inc., and director of research, Summa Cardiovascular Institute. 

“We’re excited for the fourth year of Cleveland HeartLab’s annual symposium, which demonstrates our continuing commitment to education and the promotion of early risk identification and disease prevention,” said Jake Orville, president and chief executive of Cleveland HeartLab.  “Seventy-five cents of every health care dollar spent today goes to treat chronic disease.  This year’s symposium will focus on strategies for preventing chronic disease, keeping patients healthier and lowering health care costs.  Past participants have told us that our symposium offers expertise and information they can’t find anywhere else, which translates directly into better patient care in their practices.”

About Cleveland HeartLab

Cleveland HeartLab Inc. is an advanced clinical laboratory and cardiovascular disease management company. Established in 2009, CHL offers an array of proprietary testing and analysis focused on the identification and reduction of cardiovascular inflammation. The company operates a CLIA-certified and CAP-accredited national clinical laboratory. CHL has developed prognostic tests, based on unique molecular biomarkers, which are used by thousands of medical practitioners for better prediction of risk beyond standard risk factors such as cholesterol testing. CHL also has an innovative research and development group that is tasked with the discovery and commercial development of next-generation cardiovascular biomarkers for utilization through the company’s clinical laboratory. This valuable research-enabled pipeline of tests and testing services is part of CHL’s novel intellectual property portfolio that targets large under-served markets. For more information, visit us at www.clevelandheartlab.com.